Key facts
- It has raised $8.0M; the latest was Early Stage VC ($8.0M) in Feb 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for onyx
- ·The full record, as it builds
Funding rounds
No funding rounds for onyx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About onyx
Developer of a biological data and analytics platform designed for research and development of precision medicine. The company's platform integrates longitudinal multiomics data collection, clinical context mapping, biorepository management, and artificial intelligence-driven analysis to profile immune system behavior and disease progression, enabling life sciences and biotechnology research organizations to improve understanding of autoimmune conditions and support the discovery and development of targeted therapies.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2024
- Employees
- 6
- Website
- onyx.bio/
- Ownership
- Privately Held (backing)
onyx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in onyx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on onyx in its N-PORT filings yet. We sweep new filings monthly.